Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

seqirus gmbh - influensa a-virus yta antigener (haemagglutinin och neuraminidas), inaktiverat, med följande stammar:a/california/7/2009 (h1n1)pdm09 - liknande stam(a/brisbane/10/2010, wild type)/schweiz/9715293/2013 (h3n2) - liknande stam(a/south australia/55/2014, wild type)b/phuket/3073/2013–som stam(b/utah/9/2014, wild-type) - influenza, human; immunization - vacciner - profylax av influensa för vuxna, särskilt hos dem som löper ökad risk för associerade komplikationer. optaflu bör användas i enlighet med officiella riktlinjer.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denguefeber - vacciner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 och 4. användning av dengvaxia bör ske i enlighet med officiella rekommendationer.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - influensa, människa - vacciner - profylax av influensa hos äldre (65 år och äldre). fluad tetra bör användas i enlighet med officiella rekommendationer.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningit, meningokock - vacciner - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influensa, människa - vacciner - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vacciner - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

intervet international b.v. - live myxom vektoriserade rhd virusstam 009, live myxom vektoriserade rhd virusstam mk1899 - immunologicals för leporidae - kaniner - för aktiv immunisering av kaniner från 5 veckors ålder och framåt för att minska dödlighet och kliniska tecken på kaninpest och kanin hemorragisk sjukdom (hst) som orsakas av klassisk rhd-virus (rhdv1) och rhd-typ 2-virus (rhdv2).

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - grisar - för aktiv immunisering av grisar från 7 veckors ålder och framåt för att förebygga dödlighet och minska infektion och sjukdom som orsakas av klassisk svinpestvirus (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Umoja wa Ulaya - Kiswidi - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokockinfektioner - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. se avsnitt 4. 4 och 5. 1 för information om skydd mot specifika pneumokockserotyper. the use of vaxneuvance should be in accordance with official recommendations.